Abstract
Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and underlying liver function. In intermediate stage HCC, a high rate of recurrence and unsatisfactory treatment outcome after transarterial chemoembolization (TACE) are usually due to a large size and high number of tumors. TACE using drug-eluting beads has an advantage of a higher concentration of chemotherapeutic agent in the tumor. It might be applied to the patients with advanced diseases such as bilobar or recurrent HCC, and poor liver function. Blocking angiogenic stimuli after TACE would be a rational approach and radioembolization with 90Y is a novel interventional modality for intermediate stage HCC. The modest anti-cancer effect of sorafenib coupled with an adverse event is a hurdle to overcome in advanced HCC. External radiotherapy has achieved promising results in HCC with portal vein invasion. The role of internal radiation therapy with 90Y is not yet clear in advanced HCC. The safety and efficacy of hepatic arterial infusion chemotherapy have been reported in several studies. However, as in external radiotherapy, a well-designed randomized result is lacking. An appropriate combination strategy based on baseline patient and tumor characteristics may increase the survival of patients with intermediate or advanced HCC.
References
1.
Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338.
2.
Bruix J, Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.
3.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
4.
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.
5.
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al: Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–1171.
6.
Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–442.
7.
Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41–50.
8.
Olivery RS, Wetterslev J, Gluud C: Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;16:CD004787.
9.
Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, et al: Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1343–1350.
10.
Kim H, Park MS, Choi JY, Park YN, Kim MJ, Kim KS, et al: Can microvessel invasion of hepatocellular carcinoma be predicted by preoperative MRI? Eur Radiol 2009;19:1744–1751.
11.
Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, et al: Outcome after curative resection for a huge (≥10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 2009;198:693–701.
12.
Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT: Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189–1196.
13.
Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer, E-pub ahead of print.
14.
Liapi E, Geschwind JF: Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25:978–986.
15.
Yan S, Xu D, Sun B: Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci, E-pub ahead of print.
16.
Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, et al: Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037–2044.
17.
Kudo M, Imanaka K, Chida N, Nakachi K, Takayama T, Yoon JH, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117–2127.
18.
Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, et al: Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012;56:1336–1342.
19.
Lewis AL, Gonzales MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al: DC Bead: in vitro characterisation of a drug-delivery device for transarterial chemoembolisation. J Vasc Interv Radiol 2006;17:335–342.
20.
Lammer J, Malagari K, Vogi T, Pilleul F, Denys A, Watkinson A, et al: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52.
21.
Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al: Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol, E-pub ahead of print.
22.
Sangro B, Inarrairaegui M, Bilbao JI: Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464–473.
23.
Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497–507.
24.
Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J: Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100:1995–2004.
25.
Zhu AX: Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol 2010;17:1247–1256.
26.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
27.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
28.
Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, et al: Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer, E-pub ahead of print.
29.
Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol, E-pub ahead of print.
30.
Ezzoukhry Z, Louandre C, Trecherel E, Godin C, Chauffert B, Dupont S, et al: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer, E-pub ahead of print.
31.
Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguet AC, Prager G, et al: Erolotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol 2012;57:592–599.
32.
Kudo M, Ueshima K, Arizumi T: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012, in press.
33.
Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al: Combined therapy consisting of intra-arterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986–1991.
34.
Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588–595.
35.
Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, et al: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129–137.
36.
Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, et al: A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010;65:373–382.
37.
Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995–1003.
38.
Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al: Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004–2011.
39.
Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011;54:868–878.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
